PKM and glioblastoma: To disrupt the aerobic glycolysis characteristic of GBM cells, several inhibitors have been developed against key enzymes responsible for this metabolic shift, namely, pyruvate kinase M2 (PKM2) and pyruvate dehydrogenase kinase (PDK).